A Study on BCR-ABL Kinase Domain Mutations in Chronic Myeloid Leukemia from Western India

Background: BCR-ABL kinase domain(KD) mutations accounts for 60-80% of Imatinib resistance in chronic myeloid leukemia (CML) – chronic phase (CP). Patients with CML who are receiving imatinib treatment, a mutation analysis is required to find out the resistance of imatinib as per European Leukemia N...

Full description

Bibliographic Details
Main Authors: Pankaj Gadhia, Jessica Jeejan, Vishma Shah, Monika Patel, Salil Vaniawala
Format: Article
Language:English
Published: West Asia Organization for Cancer Prevention 2021-10-01
Series:Asian Pacific Journal of Cancer Biology
Subjects:
Online Access:http://www.waocp.com/journal/index.php/apjcb/article/view/740